# A Study of KM501 in Patients With Solid Tumors

> **NCT05804864** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Xuanzhu Biopharmaceutical Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** KM501

## Key facts

- **NCT ID:** NCT05804864
- **Lead sponsor:** Xuanzhu Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-04
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2023-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05804864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05804864, "A Study of KM501 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05804864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*